RU2535115C1 - Фармацевтический состав, содержащий нейротоксин ботулина - Google Patents
Фармацевтический состав, содержащий нейротоксин ботулина Download PDFInfo
- Publication number
- RU2535115C1 RU2535115C1 RU2013122509/15A RU2013122509A RU2535115C1 RU 2535115 C1 RU2535115 C1 RU 2535115C1 RU 2013122509/15 A RU2013122509/15 A RU 2013122509/15A RU 2013122509 A RU2013122509 A RU 2013122509A RU 2535115 C1 RU2535115 C1 RU 2535115C1
- Authority
- RU
- Russia
- Prior art keywords
- botulinum toxin
- pharmaceutical composition
- toxin type
- chitosan
- heparin
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 231100001103 botulinum neurotoxin Toxicity 0.000 title claims description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229920000669 heparin Polymers 0.000 claims abstract description 49
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 41
- 229960002897 heparin Drugs 0.000 claims abstract description 33
- 229920001661 Chitosan Polymers 0.000 claims abstract description 29
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 23
- 229960000899 nadroparin Drugs 0.000 claims abstract description 16
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 6
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 6
- 229940045110 chitosan Drugs 0.000 claims abstract description 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 69
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 66
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 36
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 14
- 230000009471 action Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 229940018272 xeomin Drugs 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 230000002638 denervation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000007888 toxin activity Effects 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 230000036617 axillary hyperhidrosis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- -1 sucrose Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013122509/15A RU2535115C1 (ru) | 2013-05-15 | 2013-05-15 | Фармацевтический состав, содержащий нейротоксин ботулина |
| EP20190163.4A EP3750525A1 (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| ES14727073T ES2829614T3 (es) | 2013-05-15 | 2014-05-14 | Composición farmacéutica que comprende una neurotoxina botulínica y usos de la misma |
| US14/888,511 US10258673B2 (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| JP2016513482A JP6440691B2 (ja) | 2013-05-15 | 2014-05-14 | ボツリヌス神経毒を含む医薬組成物およびその使用 |
| CN201480027168.XA CN105209014B (zh) | 2013-05-15 | 2014-05-14 | 含有肉毒杆菌神经毒素的药物组合物及其应用 |
| HK16105183.8A HK1217173A1 (zh) | 2013-05-15 | 2014-05-14 | 含有肉毒杆菌神经毒素的药物组合物及其应用 |
| EP14727073.0A EP2996674B1 (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| CA2911046A CA2911046C (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| DK14727073.0T DK2996674T3 (da) | 2013-05-15 | 2014-05-14 | Farmaceutisk sammensætning omfattende et botulinum-neurotoxin og anvendelser deraf |
| PCT/IB2014/061417 WO2014184746A1 (en) | 2013-05-15 | 2014-05-14 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013122509/15A RU2535115C1 (ru) | 2013-05-15 | 2013-05-15 | Фармацевтический состав, содержащий нейротоксин ботулина |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2535115C1 true RU2535115C1 (ru) | 2014-12-10 |
Family
ID=50841919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013122509/15A RU2535115C1 (ru) | 2013-05-15 | 2013-05-15 | Фармацевтический состав, содержащий нейротоксин ботулина |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10258673B2 (enExample) |
| EP (2) | EP2996674B1 (enExample) |
| JP (1) | JP6440691B2 (enExample) |
| CN (1) | CN105209014B (enExample) |
| CA (1) | CA2911046C (enExample) |
| DK (1) | DK2996674T3 (enExample) |
| ES (1) | ES2829614T3 (enExample) |
| HK (1) | HK1217173A1 (enExample) |
| RU (1) | RU2535115C1 (enExample) |
| WO (1) | WO2014184746A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2651044C2 (ru) * | 2016-08-22 | 2018-04-18 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) | Способ лечения желудочковых нарушений ритма сердца (варианты) |
| US12144847B2 (en) | 2016-09-13 | 2024-11-19 | Allergan, Inc. | Non-protein clostridial toxin compositions |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6738739B2 (ja) * | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 膀胱内滴下注入用生物製剤 |
| SG11201700736YA (en) * | 2014-07-31 | 2017-02-27 | Allergan Inc | Formulations of biologics for intravesical instillation |
| RU2577296C1 (ru) * | 2014-12-24 | 2016-03-10 | Евгения Николаевна Анисимова | Способ выбора эффективного и безопасного местного обезболивания у пациентов с артериальной гипертензией на амбулаторном стоматологическом приеме |
| WO2019005222A1 (en) * | 2017-06-29 | 2019-01-03 | Advaite LLC. | TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS |
| JP7395576B2 (ja) * | 2018-06-13 | 2023-12-11 | デルマタ・セラピューティクス，インコーポレーテッド | 皮膚状態の処置のための組成物 |
| KR20210057106A (ko) * | 2018-09-13 | 2021-05-20 | 알레간 인코포레이티드 | 교근 비대의 치료 방법 |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| EP4045073A4 (en) | 2019-10-18 | 2022-12-07 | Penland Foundation | Botulinum toxin for use in treatment |
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| WO2023287728A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
| WO2024102345A1 (en) * | 2022-11-07 | 2024-05-16 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004662A1 (en) * | 2003-11-13 | 2008-01-03 | Peters Nicholas S | Post-operative control of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
| RU2407541C2 (ru) * | 2004-07-12 | 2010-12-27 | Ипсен Лимитед | Фармацевтический состав, содержащий нейротоксин ботулина |
| EP1691747B1 (en) * | 2003-11-13 | 2012-05-23 | CardioPolymers, Inc. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2884358A (en) | 1957-04-22 | 1959-04-28 | Southern California Gland Co | Process for preparing crude heparin |
| JPH06192296A (ja) | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。 |
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
| US6977080B1 (en) * | 1999-08-10 | 2005-12-20 | Allergan, Inc. | Intrapericardial botulinum toxin treatment for bradycardia |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US20060228404A1 (en) * | 2004-03-04 | 2006-10-12 | Anderson Daniel G | Compositions and methods for treatment of hypertrophic tissues |
| JP2005306746A (ja) * | 2004-04-19 | 2005-11-04 | Jiyugaoka Clinic | 顔面用シワ治療剤 |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| GB2419817A (en) * | 2004-10-29 | 2006-05-10 | Ipsen Ltd | Treatment of cardiac fibrillation disorders |
| WO2007019554A2 (en) * | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
| EP2476392A1 (en) | 2006-05-15 | 2012-07-18 | Symphony Medical, INC. | Post-operative control of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
| AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| WO2008148798A2 (en) * | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| JP4999008B2 (ja) | 2008-07-15 | 2012-08-15 | 楽天株式会社 | 情報送信装置、情報送信方法、情報送信処理プログラム及び情報送信システム |
| HUE037595T2 (hu) | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| JP6738739B2 (ja) * | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 膀胱内滴下注入用生物製剤 |
-
2013
- 2013-05-15 RU RU2013122509/15A patent/RU2535115C1/ru active
-
2014
- 2014-05-14 EP EP14727073.0A patent/EP2996674B1/en active Active
- 2014-05-14 US US14/888,511 patent/US10258673B2/en not_active Expired - Fee Related
- 2014-05-14 JP JP2016513482A patent/JP6440691B2/ja not_active Expired - Fee Related
- 2014-05-14 EP EP20190163.4A patent/EP3750525A1/en not_active Withdrawn
- 2014-05-14 CN CN201480027168.XA patent/CN105209014B/zh not_active Expired - Fee Related
- 2014-05-14 CA CA2911046A patent/CA2911046C/en not_active Expired - Fee Related
- 2014-05-14 ES ES14727073T patent/ES2829614T3/es active Active
- 2014-05-14 HK HK16105183.8A patent/HK1217173A1/zh unknown
- 2014-05-14 WO PCT/IB2014/061417 patent/WO2014184746A1/en not_active Ceased
- 2014-05-14 DK DK14727073.0T patent/DK2996674T3/da active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004662A1 (en) * | 2003-11-13 | 2008-01-03 | Peters Nicholas S | Post-operative control of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
| EP1691747B1 (en) * | 2003-11-13 | 2012-05-23 | CardioPolymers, Inc. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
| RU2407541C2 (ru) * | 2004-07-12 | 2010-12-27 | Ипсен Лимитед | Фармацевтический состав, содержащий нейротоксин ботулина |
Non-Patent Citations (1)
| Title |
|---|
| Oh S, et. all "Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation", Circ Arrhythm Electrophysiol. 2011 Aug;4(4):560-5. doi: 10.1161/CIRCEP.111.961854. Epub 2011 Jun 9, реферат. * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2651044C2 (ru) * | 2016-08-22 | 2018-04-18 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) | Способ лечения желудочковых нарушений ритма сердца (варианты) |
| US12144847B2 (en) | 2016-09-13 | 2024-11-19 | Allergan, Inc. | Non-protein clostridial toxin compositions |
| US12171816B2 (en) | 2016-09-13 | 2024-12-24 | Allergan, Inc. | Non-protein Clostridial toxin compositions |
| US12409211B2 (en) | 2016-09-13 | 2025-09-09 | Allergan, Inc. | Non-protein Clostridial toxin compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105209014B (zh) | 2018-05-25 |
| DK2996674T3 (da) | 2020-10-26 |
| CA2911046C (en) | 2021-08-31 |
| JP2016518442A (ja) | 2016-06-23 |
| US10258673B2 (en) | 2019-04-16 |
| CN105209014A (zh) | 2015-12-30 |
| EP2996674B1 (en) | 2020-08-12 |
| JP6440691B2 (ja) | 2018-12-19 |
| CA2911046A1 (en) | 2014-11-20 |
| HK1217173A1 (zh) | 2016-12-30 |
| US20160114013A1 (en) | 2016-04-28 |
| EP3750525A1 (en) | 2020-12-16 |
| ES2829614T3 (es) | 2021-06-01 |
| WO2014184746A1 (en) | 2014-11-20 |
| EP2996674A1 (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2535115C1 (ru) | Фармацевтический состав, содержащий нейротоксин ботулина | |
| US12171816B2 (en) | Non-protein Clostridial toxin compositions | |
| EP2621520B1 (en) | Collagenase g and collagenase h compositions for the treatment of diseases involving alterations of collagen | |
| AU2017227978B2 (en) | Composition comprising botulinum toxin | |
| JP2021520373A (ja) | Ｃｇｒｐを阻害する際に使用するための神経毒素 | |
| US20230158129A1 (en) | Clostridial toxin - hyaluronic acid compositions | |
| KR20130036758A (ko) | 피부 흉터 치료용 약학적 조성물 및 이를 이용한 피부 흉터 치료 방법 | |
| US20240226251A1 (en) | Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent | |
| HK40054617A (en) | Clostridial toxin-hyaluronic acid compositions | |
| HK40000892B (en) | Composition comprising botulinum toxin |